Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

315
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
315
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.1K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.1K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

726
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
726
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

927
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
927
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

127
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
127
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

56
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning.

JAMA cardiology·2026
Same author

DOACs vs Warfarin for Post-myocardial Infarction Left Ventricular Thrombus: A GRADE-assessed Meta-Analysis With Trial Sequential Analysis of Randomized Trials.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Global prevalence and mortality of cardiovascular disease by sex and sociodemographic index in young adults (20-39 years): Global burden of disease database 1990-2023.

American journal of preventive cardiology·2026
Same author

From identification to implementation: A narrative review of strategies to close the implementation gap in patients with familial hypercholesterolemia.

Journal of clinical lipidology·2026
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

Maternal Mortality and Cardio-Kidney-Metabolic Risk Factors Across High-Income Countries.

JACC. Advances·2026

Related Experiment Video

Updated: Oct 2, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

What is the Optimal Low-Density Lipoprotein Cholesterol?

Andrew Gagel1, Fawzi Zghyer1, Christeen Samuel2

  • 1Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA.

The Medical Clinics of North America
|March 1, 2022
PubMed
Summary

Lowering low-density lipoprotein cholesterol (LDL-C) over the long term reduces cardiovascular risk. New therapies effectively lower LDL-C, but the lowest beneficial level remains unidentified.

Keywords:
Atherosclerotic cardiovascular disease (ASCVD)Cerebrovascular accident (CVA)Low-density lipoprotein cholesterol (LDL-C)Peripheral arterial disease (PAD)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Related Experiment Videos

Last Updated: Oct 2, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Pharmacology

Background:

  • Atherosclerotic plaque burden correlates with cumulative exposure to low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoproteins.
  • Long-term exposure to lower LDL-C levels is linked to reduced cardiovascular event risk compared to shorter durations.
  • Novel lipid-lowering agents achieve unprecedented LDL-C reductions, demonstrating efficacy in primary and secondary prevention.

Purpose of the Study:

  • To review the relationship between LDL-C exposure and atherosclerotic cardiovascular disease.
  • To evaluate the impact of new lipid-lowering agents on cardiovascular risk.
  • To identify the threshold for LDL-C reduction beyond which no further clinical benefit is observed.

Main Methods:

  • Literature review of studies on lipid-lowering therapies and cardiovascular outcomes.
  • Analysis of data from clinical trials investigating novel lipid-reducing agents.
  • Examination of epidemiological data linking LDL-C levels to cardiovascular disease progression.

Main Results:

  • Cumulative LDL-C exposure is a key determinant of atherosclerotic plaque burden.
  • Sustained lower LDL-C levels significantly decrease cardiovascular event rates.
  • Emerging lipid-lowering drugs effectively reduce LDL-C to very low levels, improving safety and efficacy profiles.
  • No definitive LDL-C threshold has been established below which no additional clinical benefit occurs.

Conclusions:

  • Long-term management of LDL-C is crucial for reducing atherosclerotic cardiovascular disease.
  • New pharmacological interventions offer significant potential for cardiovascular risk reduction.
  • Further research is needed to determine the optimal LDL-C targets for various patient populations.